Anemia treatment and left ventricular hypertrophy in non-dialysis chronic kidney disease  

作　　者：Robert N.Foley Peter A.McCullough 

机构地区：[1]Chronic Disease Research Group Minneapolis Medical Research Foundation,Minneapolis,Minnesota University of Minnesota,Minneapolis,MN,USA [2]Department of Medicine Divisions of Cardiology,Nutrition,and Preventive Medicine,William Beaumont Hospital,Royal Oak,MI,USA

出　　处：《Journal of Geriatric Cardiology》2005年第4期195-,共1页老年心脏病学杂志（英文版）

摘　　要：To this day, the target hemoglobin level that minimizes cardiovascular risk in chronic kidney disease (CKD) patients remains unclear. When one examines the many randomized trials of epoetin therapy in aggregate, enhanced quality of life provides the most cogent argument for hemoglobin levels above 110 g/L. It remains unclear whether treatment of anemia improves longevity, or even a surrogate marker (such as left ventricular [LV] mass index), especially when applied at earlier phases of CKD.

关 键 词：CKD LEFT Anemia treatment and left ventricular hypertrophy in non-dialysis chronic kidney disease 

分 类 号：R692[医药卫生—泌尿科学]